SNDX News and Press, Syndax Pharmaceuticals Inc. From 02/28/23

Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q4 GAAP EPS of -$0.62 beats by $0.04 . As of December 31, 2022, Syndax had cash, cash equivalents, short-term and long-term investments of $481.3 million and 69.3 million common shares and prefunded warrants outstandi...

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update PR Newswire – Topline data from AUGMENT-101 KMT2Ar patients expected in the third quarter of 2023 – –Topline data from the ...

Syndax Pharmaceuticals ( NASDAQ: SNDX ) is scheduled to announce Q4 earnings results on Tuesday, February 28, after market close. The consensus EPS estimate is -$0.63 and the consensus revenue estimate is $0.43M (-99.7% Y/Y). Over the last 2 years, SNDX has beaten EPS estima...

Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023 PR Newswire WALTHAM, Mass. , Feb. 21, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharma...

Syndax Announces Participation at Upcoming Investor Conferences PR Newswire WALTHAM, Mass. , Feb. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer the...

Summary Kura Oncology, Inc. has two assets, and both produced decent data. Each asset has its own set of problems. Kura Oncology is set for cash. I covered Kura Oncology, Inc. ( KURA ) two years ago, when I said that, although I like the company’s science, p...

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with this event. For further details see: Syndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow

Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass. , Jan. 4, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of c...

Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting PR Newswire - 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both ...

Summary How informed are you about binding interactions of Menin with the mixed lineage leukemia 1 protein for the treatment of acute myeloid leukemia? Neither am I. This analysis has been supported by the Institutional Investing community who has the resources and intensity to set mark...